Headache Treatments
Michael A. Rogawski, M.D., Ph.D.
  • Home
  • Search
  • Testing Routine Blood Migraine
  • Acute Migraine Treatments
  • Behavioral Therapy
  • Botox
  • Breastfeeding
  • Butterbur
  • Cannabinoids
  • Cerebral Vascular Anatomy
  • CGRP Antibodies and Gepants
  • Children and Adolescents
  • Chronic Pain / Back Pain
  • Cluster Headache Treatment
  • Contraception - Birth Control
  • Depression Screening PHQ-2 and PHQ-9
  • Deprescribing/ Withdrawing Medications
  • Devices
  • Emergency Department Treatment / Steroid Taper
  • Epilepsy/Seizure Drugs in Development
  • Exercise
  • HIT-6 Headache Impact Test
  • Headache Tracking
  • Headache Types
  • Hemiplegic Migraine
  • High and Low Pressure Headache
  • Hypertension Guidlines
  • Indomethacin Responsive Headaches
  • IV Infusion Protocols
  • Magnesium, Nutritional Supplements and Alternative
  • Medication Overuse Headache
  • Menopause - Menopausal Vasomotor Symptoms
  • Menstrual Migraine
  • MIDAS (Migraine Disability Assessment) and ASC-12
  • Migraine Mimics
  • Neck Pain; Spinal Anatomy & Dermtomes
  • Nerve Blocks
  • Nonpharmacological Measures
  • NSAID
  • Occipital Epilepsy
  • Publications
  • Posttraumatic Headache
  • Pregnancy
  • Preventative Migraine Treatments
  • Prodrome and Aura
  • Red Flag Symptoms
  • Sleep - Insomnia
  • SphenoCath
  • Sphenopalatine Ganglion Block
  • Status migrainosus
  • Tension Type Headache
  • Thunderclap Headache
  • Tinnitus
  • Triggers/Caffeine
  • Vestibular Migraine
  • Lawrence Robbins: Advanced Headache Therapy

AED Efficacy from Pivotal Trials

Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMislater-efficacy-aeds-partial-onset-seizures-meta-analysis-epilepsyres2018.pdfcken C, Ziemann A, Isojarvi J. Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials. Epilepsy Res. 2018 Jul;143:120-129.
Picture
Picture

Epilepsy/Seizure Drugs in Development

​Staccato® alprazolam

Engage Therapeutics​

Vigadrone (Vigabatrin)

500 mg/packet. ANDA of Aucta Pharmaceuticals LLC marketed by Upsher-Smith Laboratories.

​Libervant (DBSF)

Aquestive

AAV SCN1A Dravet

Encoded Therapeutics